Confirmatory Immunogenicity Assays

Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations

Volumn , Issue , 2011, Pages 103-117

  Wakshull, Eric ^a   Coleman, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

Confirmatory assay challenges, soluble drug target interference false positives, bridging ELISA; Confirmatory immunogenicity assays ratio of spiked sample to unspiked sample; Cut point, competition based confirmatory assays sample specific IC50 value, as cut point

Indexed keywords

EID: 79957438644     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075685.ch6     Document Type: Chapter

References (25)

1. Brown, F., Lubiniecki, A., Murano, G. ( 2002 ). Biologics 2000 - Comparability of Biotechnology Products . Developments in Biologicals, Vol. 109 . Brown F, ed. Karger, Basel .
2. Brown, F., Mire-Sluis, A.R. ( 2003 ). Immunogenicity of Therapeutic Biological Products . Developments in Biologicals, Vol 112 . Brown F, ed. Karger, Basel
3. Mire-Sluis, A.R., Chen, Y.C., Devanarayan, V., et al. ( 2004 ). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products . J Immunol Methods, 289, 1-16 .
4. Gupta, S., Indelicato, S.R., Jethwa, V., et al. ( 2007 ). Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics . J Immunol Methods, 321, 1-18 .
5. Koren, E., Smith, H., Shores, E., et al. ( 2008 ). Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products . J Immunol Methods, 333, 1-9 .
6. Shankar, G., Devanarayan, V., Amaravadi, L., et al. ( 2009 ). Recommendations for the validation of immunoassays used for the detection of host antibodies against biotechnology products . J Pharmaceut Biomed Anal, 48, 1267-1281 .
7. International Conference on Harmonization (ICH) . ( 1997 ). Safety guidance S6, preclinical safety evaluation of biotechnology-derived pharmaceuticals .
8. European Medicines Agency (EMEA) . ( 2008 ). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (EMEA/CHMP/ BMWP/14327/2006, effective April 2008) .
9. Rosenberg, A.S., Worobec, A. ( 2005 ). A risk-based approach to immunogenicity concerns of therapeutic protein products. Parts 1-3 . BioPharm Int, Nov, Dec 2004, Jan 2005.
10. Swann, P.G., Tolnay, M., Muthukkumar, S., et al. ( 2008 ). Considerations for the development of therapeutic monoclonal antibodies . Curr Opin Immunol, 20, 493-499 .
11. Casadevall, N., Nataf, J., Viron, B., et al. ( 2002 ). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin . New Engl J Med, 346, 469-475 .
12. Vandhan-Raj, S. ( 2000 ). Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia . Semin Hematol, 37 ( Suppl. 4 ), 28-34 .
13. Chung, C.H., Mirakhur, B., Chan, E., et al. ( 2008 ). Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose . New Engl J Med, 358, 1109-1117 .
14. Baert, F., Noman, M., Vermeire, S., et al. ( 2003 ). Influence of immunogenicity on the long-term efficacy of infliximab on Crohn ' s disease . New Engl J Med, 348, 601-608 .
15. Cohen, B.A., Oger, J., Gagnon, A., Giovannoni, G. ( 2008 ). The implications of immunogenicity for protein-based multiple sclerosis therapies . J Neurol Sci, 275, 7-17 .
16. Calabresi, P.A., Giovannoni, G., Confavreux, C., et al. ( 2007 ). The incidence and significance of anti-natalizumab antibodies . Neurology, 69, 1391-1403 .
17. Pavlovic, M., Girardin, E., Kapetanovic, L., Trouvin, K.H.J.-H. ( 2007 ). Similar biological medicinal products containing recombinant human growth hormone: European regulations . Hormone Res, 69, 14-21 .
18. Mellstedt, H., Niederwieser, D., Ludwig, H. ( 2008 ). The challenge of biosimilars . Ann Oncol, 19, 411-419 .
19. Schellekens, H. ( 2009 ). Biosimilar therapeutics - what do we need to consider? Nephrol Dial Transplant Plus, 2 ( Suppl. 1 ), i27-i36 .
20. Schellekens, H. ( 2002 ). Bioequivalence and the immunogenicity of biopharmaceuticals . Nature Rev Drug Discov, 1, 457-462 .
21. Schellekens, H. ( 2008 ). How to predict and prevent the immunogenicity of therapeutic proteins . Biotechnol Ann Rev 14, 191-202 .
22. Van de Weert, M., Moller, E.H. ( 2008 ). Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars . van de Weert M, Moller EH, eds. Springer, New York, pp. 97-111 .
23. Wadhwa, M., Thorpe, R. ( 2006 ). Strategies and assays for the assessment of unwanted immunogenicity . J Immunotoxicol, 3, 115-121 .
24. Nechansky, A. ( 2009 ). HAHA- nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology . J Pharm Biomed Anal, 51, 252-254 .
25. Neyer, L., Hiller, J., Gish, K., et al. ( 2006 ). Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach . J Immunol Methods, 315, 80-87 .